Cargando…
Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study
BACKGROUND: Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block the binding of PD-1 with its ligands PD-L1 and PD-L2. METHODS: In this phase 2 trial, patients with locally advanced...
Autores principales: | Cui, Chuanliang, Chen, Yu, Luo, Zhiguo, Zou, Zhengyun, Jiang, Yu, Pan, Hongming, Fan, Qingxia, Zhao, Jianfu, Xu, Qing, Jiang, Renbing, Wang, Xuan, Ma, Taiyang, Guo, Zhen, Si, Lu, Chi, Zhihong, Sheng, Xinan, Dou, Yiwei, Tan, Qian, Wu, Di, Guo, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901108/ https://www.ncbi.nlm.nih.gov/pubmed/36747118 http://dx.doi.org/10.1186/s12885-022-10473-y |
Ejemplares similares
-
Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors
por: Liu, Rujiao, et al.
Publicado: (2021) -
Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer
por: Cao, Jun, et al.
Publicado: (2022) -
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
por: Song, Yan, et al.
Publicado: (2020) -
Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial
por: Xu, Jianming, et al.
Publicado: (2020) -
HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
por: Zhang, Jibin, et al.
Publicado: (2020)